Abstract
Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) with a high prevalence that significantly impacts patients' quality of life. Given the lack of a biomarker for IBS, pharmacological treatment approaches have remained symptom-oriented and often do not provide sufficient relief. The use of prebiotics, such as oligosaccharides, lactulose and probiotic bacterial strains, has been advocated as beneficial in relieving symptoms of IBS. This review focuses on recent developments in the use of prebiotics and probiotics for the treatment of IBS. Well-designed clinical trials have been conducted that support the use of probiotic bacterial strains, mainly Lactobacillus, Bifidobacterium and Streptococcus, to reduce abdominal pain, bloating and flatulence in patients with IBS. Both prebiotics and probiotics have shown none or only mild adverse effects and should be recommended as an adjuvant therapy for patients with IBS to improve their quality of life.
| Original language | English |
|---|---|
| Pages (from-to) | 237-241 |
| Number of pages | 5 |
| Journal | European Gastroenterology and Hepatology Review |
| Volume | 7 |
| Issue number | 4 |
| State | Published - Jan 1 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Bifidobacterium
- Clinical trials
- Irritable bowel syndrome
- Prebiotics
- Probiotics
- Quality of life
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
Recent developments in the use of pre-and probiotics for irritable bowel syndrome. / Yoon, Saunjoo L.; Moshiree, Baharak; Grundmann, Oliver.
In: European Gastroenterology and Hepatology Review, Vol. 7, No. 4, 01.01.2012, p. 237-241.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recent developments in the use of pre-and probiotics for irritable bowel syndrome
AU - Yoon, Saunjoo L.
AU - Moshiree, Baharak
AU - Grundmann, Oliver
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) with a high prevalence that significantly impacts patients' quality of life. Given the lack of a biomarker for IBS, pharmacological treatment approaches have remained symptom-oriented and often do not provide sufficient relief. The use of prebiotics, such as oligosaccharides, lactulose and probiotic bacterial strains, has been advocated as beneficial in relieving symptoms of IBS. This review focuses on recent developments in the use of prebiotics and probiotics for the treatment of IBS. Well-designed clinical trials have been conducted that support the use of probiotic bacterial strains, mainly Lactobacillus, Bifidobacterium and Streptococcus, to reduce abdominal pain, bloating and flatulence in patients with IBS. Both prebiotics and probiotics have shown none or only mild adverse effects and should be recommended as an adjuvant therapy for patients with IBS to improve their quality of life.
AB - Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) with a high prevalence that significantly impacts patients' quality of life. Given the lack of a biomarker for IBS, pharmacological treatment approaches have remained symptom-oriented and often do not provide sufficient relief. The use of prebiotics, such as oligosaccharides, lactulose and probiotic bacterial strains, has been advocated as beneficial in relieving symptoms of IBS. This review focuses on recent developments in the use of prebiotics and probiotics for the treatment of IBS. Well-designed clinical trials have been conducted that support the use of probiotic bacterial strains, mainly Lactobacillus, Bifidobacterium and Streptococcus, to reduce abdominal pain, bloating and flatulence in patients with IBS. Both prebiotics and probiotics have shown none or only mild adverse effects and should be recommended as an adjuvant therapy for patients with IBS to improve their quality of life.
KW - Bifidobacterium
KW - Clinical trials
KW - Irritable bowel syndrome
KW - Prebiotics
KW - Probiotics
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=84875246137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875246137&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84875246137
VL - 7
SP - 237
EP - 241
JO - European Gastroenterology and Hepatology Review
JF - European Gastroenterology and Hepatology Review
SN - 1758-3799
IS - 4
ER -